Reishi Mushroom
Ganoderma lucidum · the varnished bracket, and why the part matters
All articles checked for accuracy against the GB NHC Register and all sources have citations with verified links to their relevant studies.
Reishi, or Ganoderma lucidum, carries centuries of cultural weight across East Asia. This article separates folklore from factual detail and explains why the mushroom part matters for shoppers.
This piece explains what reishi actually is, why the distinction between fruiting body and mycelium-on-grain matters, which chemical families are used to characterise genuine extracts, how to read the research honestly, and how WellsparQ sources and lists reishi in its products. It highlights where regulatory limits apply to claims about non-nutrient botanicals.
Ingredient Snapshot
- What it is
- A woody, shelf-like fungus commonly called reishi mushroom.
- Where from
- Ganoderma lucidum — the varnished bracket, grown as the fruiting body.
- Known for
- Rich in fungal polysaccharides (beta‑glucans) and triterpenes; traditionally used in East‑Asian herbal culture.
- In WellsparQ
- FungiBlend65 mg
- CalmaRoot Blend25 mg
- ImmunoDefence Pro20 mg
Few ingredients carry as much folklore as reishi. In China it is lingzhi, the "mushroom of immortality"; in Japan, reishi. It has appeared in East-Asian herbal texts for the better part of two thousand years, painted into scrolls and carved into furniture as a symbol of longevity and good fortune. That heritage is genuinely old and genuinely interesting. It is also, on its own, a cultural fact and nothing more — it tells us how people have valued the mushroom, not what it does in a modern body. This piece separates the two, and explains a quality distinction that matters more than most shoppers realise.
A mushroom, not a plant
Reishi is Ganoderma lucidum, a woody, shelf-like (bracket) fungus that grows on hardwood, most famously oak. In the wild it is uncommon and slow-growing, with a glossy, lacquered, kidney-shaped cap — the "varnished" look that gives it the species name lucidum, "shining." It is one of the most-studied species in all of mycology, which is exactly why it repays a careful, honest description rather than a romantic one ¹.
Being a fungus, reishi is neither animal nor plant — it belongs to its own kingdom, with a cell wall built largely from chitin and complex sugars. That biology is the reason the "which part, grown how" question below is not pedantry. It changes what is actually in the jar.
Fruiting body vs mycelium-on-grain — the distinction to hold on to
This is the part worth slowing down for.
A mushroom has two very different stages. The mycelium is the thread-like root network that spreads through the growing substrate. The fruiting body is what most people would recognise as "the mushroom" — the visible cap that the fungus pushes up to release its spores. Traditional preparations, and most of the research literature, use the fruiting body ¹².
A good deal of cheaper "mushroom" material on the market is not fruiting body at all. It is mycelium grown on grain (usually rice or oats), then dried and milled with the grain still attached. The result can be high in starch from the grain and comparatively low in the mushroom's own characteristic compounds — yet it may still be labelled simply "reishi." Two products bearing the same name can therefore be quite different things.
WellsparQ specifies fruiting body. That is a deliberate sourcing choice, and it is the honest one to make plain: it is the part of the mushroom you would actually recognise, and the part the traditional and research literature is built on.
What the fruiting body is grown for
Reishi's characteristic chemistry falls into two broad families, and a well-made extract is usually described by them:
| Constituent family | What they are | Why they are the markers |
|---|---|---|
| Beta-glucans (polysaccharides) | Long-chain complex sugars in the fungal cell wall, chiefly (1→3),(1→6)-β-D-glucans | The dominant water-soluble fraction; the compounds most often measured to gauge a genuine mushroom extract ³⁴ |
| Triterpenes (ganoderic/ganoderenic acids) | A large family of bitter oxygenated triterpenoids, many unique to Ganoderma | Responsible for reishi's distinctive bitterness; used as chemical fingerprints of the species ⁵ |
Over 300 triterpenoids have been catalogued from Ganoderma in the research literature, alongside a range of polysaccharides ⁵. For a shopper, the practical point is simple: beta-glucan and triterpene content are what separate real, characterised fruiting-body material from milled grain — which is why they are worth asking about.
Reading the research honestly
Reishi has a real body of laboratory and animal work, and a smaller, weaker body of human research. Honesty means describing both, and their limits, without turning any of it into a promise.
- A 2021 systematic review of randomised controlled trials of fungal beta-glucans examined effects across various health outcomes and concluded that, while some signals are of interest, the human trial evidence is limited and heterogeneous, with studies varying widely in dose, preparation and quality ³.
- A Cochrane systematic review (2016) looked specifically at Ganoderma lucidum as an adjunct in cancer care. Its authors found the available trials too few and too methodologically weak to support reishi as a first-line treatment, while noting it was sometimes associated with changes in immune-cell measures; they called explicitly for better-designed studies ². (Cochrane reviews are among the most rigorous evidence summaries in medicine, so a cautious verdict from them is worth taking seriously.)
- Much of the remaining literature — reviews of reishi polysaccharides and triterpenoids — is preclinical: cell-culture and animal studies exploring possible mechanisms ⁴⁵⁶. Mechanism in a dish is a reason to keep researching, not evidence of an effect in people.
The fair summary: reishi is well studied as a fungus and a source of interesting molecules, but the human clinical evidence remains thin, mixed and short-term. A long cultural history and a busy laboratory literature are not the same as proven benefit — and, as records, none of this may be presented as a WellsparQ benefit in any case, because mushrooms carry no authorised health claim.
How WellsparQ uses it
Reishi appears across the range at modest, declared doses — a supporting botanical, weighed and named, never a headline medicine.
| WellsparQ product | Declared reishi | Form |
|---|---|---|
| FungiBlend | 65 mg | Organic Ganoderma lucidum fruiting body |
| CalmaRoot Blend | 25 mg | Reishi mushroom |
| ImmunoDefence Pro | 20 mg | Reishi fruiting body, extract equivalent |
Source: WellsparQ Supplements Database. The factsheet card puts it plainly: this is "from the fruiting body, not the cheaper mycelium — the part of the mushroom you'd actually recognise". All three formulas are plant-based and suitable for vegetarians and vegans; reishi is, of course, itself neither plant nor animal but a fungus.
Sensible use
Reishi is generally well tolerated. Reported effects are usually mild and may include digestive upset or dryness of the mouth and throat. Because laboratory work suggests possible effects on blood clotting and on immune signalling, anyone taking anticoagulant (blood-thinning) medicines, on immunosuppressants, or preparing for surgery should speak to a GP or pharmacist first, as should anyone who is pregnant or breastfeeding, where reliable safety data are lacking. Take as directed.
References
- Ganoderma lucidum (lingzhi/reishi) — mycology, fruiting body, traditional East-Asian use and constituent overview. Peer-reviewed pharmacognosy literature (see refs 4–6) and NCCIH/NIH consumer information (nccih.nih.gov). ↩ Back to text
- Jin X. et al. Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database of Systematic Reviews, 2016. PMID 27045603. ↩ Back to text
- Effects of fungal beta-glucans on health — a systematic review of randomized controlled trials. Food & Function, 2021. PMID 33876798. ↩ Back to text
- Molecular mechanisms of bioactive polysaccharides from Ganoderma lucidum (Lingzhi): a review. International Journal of Biological Macromolecules, 2020. PMID 32035956. ↩ Back to text
- A Review of Ganoderma Triterpenoids and Their Bioactivities. Biomolecules, 2022. PMID 36671409. ↩ Back to text
- Ganoderma lucidum: a rational pharmacological approach to surmount cancer. Journal of Ethnopharmacology, 2020. PMID 32504783. (Cited as a source characterising the preclinical literature and its limits.) ↩ Back to text